Cencora (NYSE:COR) Updates FY 2026 Earnings Guidance

Cencora (NYSE:COR) issued an update on its FY 2026 earnings guidance on Friday morning. The company provided EPS guidance of 17.750-17.950 for the period, compared to the consensus EPS estimate of 17.850. The company issued revenue guidance of -.

Wall Street Analysts Forecast Growth

Several research firms recently commented on COR. Wall Street Zen upgraded Cencora from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Weiss Ratings raised shares of Cencora from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, August 6th. Wells Fargo & Company boosted their price target on shares of Cencora from $331.00 to $395.00 and gave the stock an “overweight” rating in a research report on Tuesday. JPMorgan Chase & Co. increased their target price on shares of Cencora from $382.00 to $390.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Finally, Barclays cut their price target on shares of Cencora from $425.00 to $350.00 and set an “overweight” rating on the stock in a report on Wednesday, June 10th. Thirteen analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $374.25.

Cencora Stock Down 1.3%

COR stock opened at $310.13 on Friday. The company has a quick ratio of 0.58, a current ratio of 0.93 and a debt-to-equity ratio of 3.53. The firm has a 50-day simple moving average of $298.20 and a 200-day simple moving average of $313.24. The stock has a market capitalization of $60.34 billion, a P/E ratio of 23.04, a P/E/G ratio of 1.81 and a beta of 0.57. Cencora has a 52 week low of $244.82 and a 52 week high of $377.54.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $4.48 earnings per share for the quarter, beating analysts’ consensus estimates of $4.35 by $0.13. The firm had revenue of $84.75 billion during the quarter, compared to analysts’ expectations of $84.31 billion. Cencora had a net margin of 0.79% and a return on equity of 125.45%. The business’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $4.00 earnings per share. Equities analysts forecast that Cencora will post 17.84 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Friday, August 14th will be paid a $0.60 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $2.40 annualized dividend and a dividend yield of 0.8%. Cencora’s payout ratio is currently 17.83%.

Cencora declared that its board has authorized a stock repurchase program on Thursday, May 21st that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the company to repurchase up to 3.9% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board believes its stock is undervalued.

Insider Transactions at Cencora

In related news, Director Lauren M. Tyler acquired 550 shares of the firm’s stock in a transaction on Monday, June 22nd. The shares were bought at an average cost of $270.23 per share, with a total value of $148,626.50. Following the completion of the acquisition, the director owned 4,359 shares of the company’s stock, valued at $1,177,932.57. This trade represents a 14.44% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.38% of the company’s stock.

Cencora News Roundup

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Wells Fargo issued a Buy rating on Cencora, providing a fresh bullish signal and potentially supporting the stock’s valuation. Wells Fargo Gives a Buy Rating to Cencora
• Positive Sentiment: Brokerage coverage remains broadly constructive, with Cencora receiving an average “Moderate Buy” rating. Several recent price targets are above the current trading level, and Zacks highlighted the stock as a potential long-term value opportunity. Cencora Receives Moderate Buy Rating Why Cencora Is a Top Value Stock
• Positive Sentiment: Long-term momentum arguments remain intact, supported by Cencora’s healthcare-distribution scale, recurring demand and recent earnings that exceeded consensus expectations for both revenue and adjusted EPS. Why Cencora Is a Top Momentum Stock
• Neutral Sentiment: Analysts focused on customer concentration, pricing changes, GLP-1 demand and the outlook during Cencora’s earnings call. The questions underscore areas investors are monitoring but did not establish a new major catalyst. Five Analyst Questions From Cencora’s Earnings Call
• Neutral Sentiment: Institutional positioning was mixed: 561 investors added shares while 802 reduced holdings. Large purchases by JPMorgan, Morgan Stanley and others were offset by reductions from BlackRock and Royal Bank of Canada, offering no clear consensus signal.
• Negative Sentiment: Revenue-headwind concerns remain the primary pressure on COR. Cencora’s lowered fiscal 2026 revenue-growth outlook reflects WAC and IRA-related price reductions, faster brand conversions at a major mail-order customer, slower GLP-1 growth and customer losses. Analyst target reductions after the outlook reset likely reinforced the recent decline. Cencora Slides as Investors Remain Cautious on Revenue Headwinds

Institutional Investors Weigh In On Cencora

Institutional investors have recently made changes to their positions in the stock. Kemnay Advisory Services Inc. bought a new position in Cencora during the 4th quarter valued at $25,000. Motiv8 Investments LLC bought a new stake in Cencora in the fourth quarter valued at $29,000. Turning Point Benefit Group Inc. bought a new position in Cencora during the 3rd quarter valued at approximately $74,000. DV Equities LLC bought a new stake in Cencora in the 4th quarter worth approximately $91,000. Finally, Greenline Wealth Management LLC bought a new stake in Cencora during the fourth quarter valued at about $109,000. Institutional investors own 97.52% of the company’s stock.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.